Generic direct acting antivirals in treatment of chronic hepatitis C patients

July 19, 2018

There has been published results of the study "ORIGINAL VERSUS GENERIC DIRECT ACTING ANTIVIRALS IN TREATMENT OF CHRONIC HEPATITIS C PATIENTS: REAL LIFE DATA FROM LATVIA" authored by Tolmane I, Rozentale B, Arutjunana S et al., recently.

There are many new highly effective direct acting antiviral medicines for hepatitis C treatment registered worldwide during recent years. Despite effective treatment available from 2016 in Latvia, there are restrictions - only patients with fibrosis (F, Metavir) stages 3 to 4 have access to reimbursed medicines. Some patients obtain generic drugs from India. The aim of this study was to evaluate the efficacy of original and generic direct acting antiviral medications in Latvian hepatitis C patients. This was a retrospective study of 179 chronic viral hepatitis C patients. Patients were divided into two groups - those who received original direct acting antivirals ombitasvir, paritaprevir, ritonavir, dasabuvir + ribavirin (n=144) and those who received generic medicines from India (n=35) sofosbuvir, ledipasvir or sofosbuvir, daclatasvir + ribavirin. Undetectable viral load 12 weeks after cessation of therapy (sustained virologic response 12) was measured in all patients. Therapy course completed 142 patients (2 patients discontinued treatment) from original medicines group and all patients from generics group. In the original medicines group - sustained viral response was achieved in all 142 patients who completed treatment course (100%), while in generic medicines group in 32 patients (91.4%).

Study results showed high efficacy of both regimens using original and generic medicines - sustained virologic response was achieved in more than 90% of patients, with slight superiority in original medicines group. This study shows patient's interest and eligibility to seek for alternative treatment possibilities, when original drugs are not available through reimbursement system, and they are too expensive to buy out of pocket. This study also shows high efficacy of generic drugs obtained from India.
-end-
Reference: Tolmane L et al, (2018). Original Versus Generic Direct Acting Antivirals in Treatment of Chronic Hepatitis C Patients: Real Life Data From Latvia. The Open Infectious Diseases Journal, Volume 10, 2018. DOI: 10.2174/1874279301810010063

Bentham Science Publishers

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.